Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sanj Patel Sells 97,390 Shares

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CEO Sanj Patel sold 97,390 shares of the business’s stock in a transaction on Wednesday, October 22nd. The shares were sold at an average price of $38.83, for a total transaction of $3,781,653.70. Following the sale, the chief executive officer owned 111,794 shares of the company’s stock, valued at $4,340,961.02. This trade represents a 46.56% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link.

Kiniksa Pharmaceuticals International Trading Up 0.1%

Shares of KNSA stock opened at $38.90 on Thursday. The firm has a market capitalization of $2.88 billion, a PE ratio of 972.74 and a beta of 0.16. The firm has a fifty day simple moving average of $36.20 and a two-hundred day simple moving average of $30.08. Kiniksa Pharmaceuticals International, plc has a 12 month low of $17.82 and a 12 month high of $39.79.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, beating analysts’ consensus estimates of $0.18 by $0.05. The business had revenue of $156.80 million during the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, equities analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on KNSA shares. Citigroup upped their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Friday, October 17th. Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research note on Friday, October 3rd. Zacks Research lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Wednesday, October 8th. Finally, Wedbush upped their target price on shares of Kiniksa Pharmaceuticals International from $38.00 to $44.00 and gave the stock an “outperform” rating in a research note on Monday, October 13th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $46.86.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

A number of hedge funds and other institutional investors have recently made changes to their positions in KNSA. EverSource Wealth Advisors LLC boosted its holdings in shares of Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after buying an additional 532 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of Kiniksa Pharmaceuticals International by 84.8% in the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company’s stock worth $27,000 after buying an additional 568 shares during the last quarter. Osaic Holdings Inc. purchased a new position in shares of Kiniksa Pharmaceuticals International in the 2nd quarter worth about $31,000. USA Financial Formulas purchased a new position in shares of Kiniksa Pharmaceuticals International in the 3rd quarter worth about $32,000. Finally, US Bancorp DE purchased a new position in shares of Kiniksa Pharmaceuticals International in the 1st quarter worth about $33,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.